Artiva Biotherapeutics Inc

NASDAQ:ARTVUnited States

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The Company's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Contact Information

Headquarters

5505 Morehouse DriveSAN DIEGO, CA, United States 92121

Phone

858-267-4467

Fax

302-269-3855

Executives

Independent Chairman of the Board

Brian Daniels

President, Chief Executive Officer, Director

Fred Aslan

Chief Financial Officer, Executive Vice President - Corporate Development

Neha Krishnamohan

Chief Technical Operations Officer

Christopher Horan

Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer

Jennifer Bush